Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Summary
Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with chronic hepatitis C and severe fibrosis.
Official title: Randomized Double Blind Trial Comparing the Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin for Initial Treatment of Patients With Hepatitis C With Genotype 1 or 4 and Severe Fibrosis (ANRS HC17 PRAZOR)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
112
Start Date
2004-09
Completion Date
2008-12
Last Updated
2026-06-15
Healthy Volunteers
No
Conditions
Interventions
Peg-interferon alpha 2b + Ribavirin(drug)
Prazosin (drug)
one to two capsules 2.5 mg per day
Locations (1)
Hopital du haut Leveque
Pessac, France